Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus V CILLIN K.
KLEBCIL vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic